The widespread application of EGFR tyrosine kinase inhibitors (TKIs) has significantly improved the prognosis of NSCLC patients and has become the standard treatment for locally advanced and advanced NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.